What are your top takeaways in Gynecologic Cancers from ASCO 2022?

1. ATHENA (LBA5500)

- Consistent efficacy signal with PARPi maintenance therapy in the front line
- Another potential option for our patients with greater dosing flexibility
- The BICR PFS difference in the HRP population really caught my attention. Nearly a 6 month improvement with median PFS in the rucaparib arm of 12 months.

2. Subgroup Analysis from the PRIME study (#5551)

- Added additional data to the PARPi maintenance story
- Provocative regarding the frequency of HRD+, although again, this was in a Chinese only patient population and used an internally developed HRD assay
- HRD test negative (HRP) response was quite interesting to see

3. SORAYA update (#5512)

- ORR of 32.4%, and a BICR median PFS of 5.5 months in a heavily pretreated popul...

ASCO 2022 for Gynecologic Oncology had many great presentations. Data from the following 3 trials are all likely practice-changing, particularly the ATHENA-MONO trial. This study reaffirms the pivotal role PARPis play in maintenance therapy after first-line platinum-based chemotherapy in ovarian cancer. Each of the other two studies evaluates novel targeted agents for platinum-resistant ovarian cancer.

1. “ATHENA-MONO (GOG-3020/ENGOT-ov45): a randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy vs placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer”
   Speaker: Bradley Monk, MD

This is a 4-arm international randomized study evaluating maintenance PARPi rucaparib + nivo...